# Tumour extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer

Source: https://onco.cc/key-papers/paper-yen-ev-protein-mrna-ovarian-ebiomedicine-2025/  
OnCo record `paper-yen-ev-protein-mrna-ovarian-ebiomedicine-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An ovarian cancer study that captured tumour vesicles from blood by surface proteins, including TROP2, and then read RNA inside them.

## Summary

Three ovarian cancer vesicle surface markers (FRalpha, MSLN and TROP2) were used; the integrated score had an area under the curve of 0.99 in training and 0.93 (95% CI 0.88 to 0.97) in validation, and 0.93 for stage I and II.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: eBioMedicine
- Year: 2025
- DOI: 10.1016/j.ebiom.2025.105884
- Authors: Yen YT, Zhao C, Gao T, et al.
- Findings: Validation area under the curve 0.93.
- What it means: Capturing tumour vesicles by a surface marker before reading their RNA is feasible; it was tested for detection, not residual disease.
- Caveats: Case-control; reference transcripts rather than target expression.

## Sources

- Yen et al., eBioMedicine 2025: https://doi.org/10.1016/j.ebiom.2025.105884
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40803203/

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid RNA biopsy (cell-free, vesicle and platelet RNA)](https://onco.cc/technologies/liquid-rna-biopsy/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)
- ideas: [Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer](https://onco.cc/ideas/idea-stack-ctdna-and-tumour-rna-residual-disease/)

---
JSON: https://onco.cc/api/v1/entities/paper-yen-ev-protein-mrna-ovarian-ebiomedicine-2025.json